Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.84) per share. This is a 10.64 percent increase over losses of $(0.94) per share from the same period last year.
Trading Target’s Bearish Q2 Guidance: ‘It’s Bouncing Right Where It Should’
When a company comes out with bad news two times in only a few weeks, the issue does not necessarily act in the same manner.